Skip to search formSkip to main contentSkip to account menu

pyroglutamate helix B surface peptide

Known as: UEQLERALNSS, pHBSP peptide, pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The cytoprotective effects of erythropoietin (EPO) and an EPO-related nonerythropoietic analog, pyroglutamate helix B surface… 
2016
2016
Background Endothelial injury is a critical feature in the early stages of vascular disease. Inflammation and hypoxia are often… 
2015
2015
Erythropoietin (EPO) has both erythropoietic and tissue-protective properties. The EPO analogues carbamylated EPO (CEPO) and… 
2014
2014
The haematopoietic activity of erythropoietin (EPO) is mediated by the classic EPO receptor (EpoR) homodimer, whereas tissue… 
2013
2013
Mild traumatic brain injury (mTBI) results in an estimated 75-90% of the 1.7 million TBI-related emergency room visits each year… 
2012
2012
In preclinical studies, erythropoietin (EPO) reduces ischemia-reperfusion-associated tissue injury (for example, stroke… 
2012
2012
Pyroglutamate helix B surface peptide (pHBSP) is an 11 amino acid peptide, designed to interact with a novel cell surface… 
Highly Cited
2011
Highly Cited
2011
Strong cardioprotective properties of erythropoietin (EPO) reported over the last 10 years have been difficult to translate to… 
Review
2010
Review
2010
Erythropoietin (EPO) is a cytokine with erythropoietic and tissue protective activities. Its action as a tissue protective agent…